Table 6 Sensitivity analyses - the effect of different treatment options on HCV-related morbidity and mortality
|  | Inputs | Number of HCV-related HCCs in 2020 (percentage change from scenario in Table 2) | Liver-related deaths caused by HCV in 2020 (percentage change from scenario in Table 2) |
|---|---|---|---|
Scenario: increasing diagnosis and treatment (Table 2) | -- | 310 | 280 |
Change segment treated | Allow treatment of F1 | 400 (30%) | 390 (40%) |
Restrict treatment to ≥ F2 | 260 (−15%) | 270 (−5%) | |
Change age of treated | Allow treatment of 79+ | 260 (−15%) | 260 (−5%) |
Restrict treatment to 69 | 400 (30%) | 330 (20%) | |
Change in the number treated (current- 12,000 in 2018) | Treat 3,000 (75% fewer) | 590 (90%) | 540 (95%) |
Treat 6,000 (50% fewer) | 470 (50%) | 430 (55%) | |
Treat 9,000 (25% fewer) | 360 (15%) | 330 (20%) | |
Treat 15,000 (25% more) | 300 (−5%) | 280 (0%) | |
Treat 18,000 (50% more) | 290 (−5%) | 280 (0%) | |
Treat 21,000 (75% more) | 280 (−10%) | 270 (−5%) | |
Change in the number diagnosed (Dx) (current- 13,000 in 2016)* | Dx 3,000 (75% fewer) | 410 (30%) | 370 (30%) |
Dx 7,000 (50% fewer) | 350 (15%) | 320 (15%) | |
Dx 10,000 (25% fewer) | 330 (5%) | 200 (5%) |